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SPECIAL REVIEW: GENETICS OF PLATELET BLEEDING DISORDERS
Inherited platelet disorders: Insight from platelet genomics using
next-generation sequencing
Annabel Maclachlan, Steve P. Watson, & Neil V. Morgan
Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
Abstract
Inherited platelet disorders (IPDs) are a heterogeneous group of disorders associated with
normal or reduced platelet counts and bleeding diatheses of varying severities. The identifica-
tion of the underlying cause of IPDs is clinically challenging due to the absence of a gold-
standard platelet test, and is often based on a clinical presentation and normal values in other
hematology assays. As a consequence, a DNA-based approach has a potentially important role
in the investigation of these patients. Next-generation sequencing (NGS) technologies are
allowing the rapid analysis of genes that have been previously implicated in IPDs or that are
known to have a key role in platelet regulation, as well as novel genes that have not been
previously implicated in platelet dysfunction. The potential limitations of NGS arise with the
interpretation of the sheer volume of genetic information obtained from whole exome
sequencing (WES) or whole genome sequencing (WGS) in order to identify function-disrupting
variants. Following on from bioinformatic analysis, a number of candidate genetic variants
usually remain, therefore adding to the difficulty of phenotype–genotype segregation verifica-
tion. Linking genetic changes to an underlying bleeding disorder is an ongoing challenge and
may not always be feasible due to the multifactorial nature of IPDs. Nevertheless, NGS will play
a key role in our understanding of the mechanisms of platelet function and the genetics
involved.
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Introduction
Platelet disorders are a large group of diseases with variable
bleeding diatheses ranging from mild to severe. They can be
characterized quantitatively (i.e. thrombocytopenia) or qualita-
tively (i.e. function disorders) and can be either inherited or
acquired. The majority of individuals with inherited platelet dis-
orders (IPDs) have a platelet count within the normal range of
150–400 x 109/L [1,2]. IPDs are considered to be rare with a
frequency of 1: 10 000 but are likely to be under-recognized due
to the difficulty of diagnosis, particularly in milder cases [1,3].
Platelets are small anucleate fragments, discoid in morphol-
ogy, which originate from megakaryocytes in the bone marrow
[3]. Upon vessel injury, when subendothelial matrix proteins
become exposed, platelets undergo a series of rapid functional
responses to form a vascular plug to limit blood loss [2–4].
Recent advances using mutant mice and human genetics have
contributed greatly to the understanding of cellular and molecular
mechanisms of the pathogenesis of IPDs. This includes the
identification of the underlying genetic defects in heritable dis-
orders, which is closely associated with their phenotype [5,6].
In the UK there are several groups investigating the causes of
bleeding in patients with clinically diagnosed IPDs all involving
next-generation sequencing (NGS). Additionally, groups from the
University of Pavia and the University of Trieste in Italy collabo-
rate on research into inherited thrombocytopenias and their asso-
ciated genetics by NGS [7,8]. This review will discuss bleeding
and IPDs with respect to mutations found following genomic
investigation using NGS and the future of clinical investigation
into the cause of unresolved bleeding disorders.
Platelet disorders and testing prior to the NGS era
There are many types of disorders that fall under the umbrella term
of IPDs. Most of the major IPDs associated with a strong phenotype
are well characterized and were originally found by traditional
methods of platelet function testing prior to our now “genomic
era”. Examples of these include: Bernard–Soulier syndrome,
Glanzmann thrombasthenia, Chediak–Higashi syndrome,
Hermansky–Pudlak syndrome and Wiskott–Aldrich syndrome
[4,9–12]. The classical gold standard platelet function assay – light
transmission aggregometry (LTA), first described by Born – is still
the most widely used test for the identification and diagnosis of IPDs
as the responses to multiple concentrations of different agonists can
be monitored [13]. Multiple electrode aggregometry (MEA) is also
often used to measure whole blood impedance aggregation along
with flow cytometry to measure the levels of platelet activation by
markers such as glycoproteins and α-granule marker, P-selectin
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[14–17]. However, when platelet disorders are discovered as a result
of the testing methods above, the outcomes usually stop short of
giving the physicians and patients a final and definitive diagnosis.
This explains the need to involve a level of genetic analysis either to
confirm the observed phenotype or to suggest candidate variants
when a diagnosis is not obvious.
Genetic and genomics of platelet disorders
Genomics is defined as the study of the genetic material of an
organism and its associated functions [18]. Genomics therefore
aims to address all genes and their interrelationships in order to
study and identify their combined influence on growth and devel-
opment; this is in comparison to genetics, which mainly scruti-
nizes the function of a single gene [18]. The Human Genome
project (HGP) began in the mid-1980s and was an international,
collaborative project with the objective of completely mapping
and improving the understanding of an individual’s entire nucleic
material known collectively as our genome [19,20]. The initial
sequence data was first published in the journal Nature in
February 2001 when it was 90% complete and was finally pro-
claimed 99% complete in 2003 [21,22]. This project required and
will continue to require new technologies to refine the draft and
carry on research with regard to the human genome. Following
the HGP, the 1000 Genomes Project was the first of its kind to
sequence the genomes of a large group of individuals in order to
provide a valuable resource to the scientific community on human
genetic variation. The primary goal was to elucidate the genetic
variants that have frequencies of at least 1% in the populations
studied. The main drawback of the 1000 Genomes Project is that
the samples are anonymous and therefore no phenotype data is
available. However, the 1000 Genomes data can be combined
with genome-wide association studies (GWAS) for additional
variants beyond those already genotyped and allow for disease-
associated genes, regions and variants to be researched in more
depth. GWAS focus on the associations between single nucleotide
polymorphisms (SNPs) and the varying phenotypes of a specific
syndrome or disease typically seen in IPDs [23]. Family-based
designs for GWAS are particularly beneficial as they enrich for
genetic defects and have more power than unrelated individuals to
detect genetic defects [24]. Family-based designs often include
parent–offspring trios, sibling pairs, consanguineous families and
large extended families with multiple affected family members
[24]. The statistical principals underlying these designs such as
the McNemar-type statistic are often complicated and will not be
described here in detail [25–27].
Platelet genomics is a challenging area of research due to the
absence of a nucleus. Platelets do have residual levels of mega-
karyocyte-derived RNA, and have been shown to make low
amounts of proteins, most notably interleukin 1 [28–30]. The
platelet genome is yet to be fully defined, but data enlightening
on how genetic variation, at the level of gene transcription and
translation, perturbs platelet function has been highly beneficial
[28]. This has led to further analysis in recent years with the birth
of more specialized techniques within genomics and more man-
ageable costs of genomic investigation.
Next-generation sequencing
DNA sequencing has been revolutionizing medical research since
the invention of Sanger sequencing by Sanger et al. and the
polymerase chain reaction (PCR) by Mullis et al. [31,32].
Traditional methods are now being replaced with NGS technolo-
gies and have led to an exponential reduction in the costs involved
in sequencing whole genomes/exomes [6]. Whole genome
sequencing (WGS) and whole exome sequencing (WES) are
used to identify genetic factors causing human diseases, some of
which were previously undetectable. These high-throughput
experimental approaches are now more widely available than
ever and have been adopted in both research and clinical settings
in relation to patients with platelet and bleeding disorders [33]. It
is well known that approximately 1.5% of the human genome
contains protein-coding sequences (exons), within which 85% of
alleles that underlie Mendelian disorders, that disrupt protein-
coding sequences, reside [6]. Therefore, exome sequencing
alone is enough to harbor enough data to uncover most rare and
potential genetic disorders and the predisposing variants [6,34].
The first report of selectively sequencing all exomes successfully
was published by Ng et al. in 2009 [35]. The method of WES can
be read elsewhere and although there are several slightly different
methods, they all follow the same principle for the rapid identifi-
cation of protein-coding variants; mutations include missense and
nonsense to small insertion/deletion mutations and splice site
mutations [33,36]. WES can also be used to identify the genetic
causes of multifactorial disorders that can be more common in
bleeding disorders. There are some fundamental limitations of
WES, the most obvious being that WES does not assess the
impact of non-coding regions since it is limited to coding and
splice site variants only [6]. The method is still time consuming
and the coverage of regions of interest is not always complete.
This has improved since the first experiments, where 8% of
regions of interest were not captured by the enrichment strategy,
but it is not expected that 100% coverage will ever be reached
[33,35]. WES often remains not as cost effective as even a large
targeted panel and still has difficulty in identifying repeat muta-
tions and copy number variants, often leading to false positives
[33]. Confirmation and validation of possible disease-causing
variants by Sanger sequencing are nearly always required follow-
ing WES as it has a very high level of coverage and the possibility
of false-positive calls is little to none.
The advance of genomic technologies in discovering genetic
variants in IPDs
One of the main applications and challenges of NGS is proving
that a certain genetic variant or variants are responsible for the
clinical presentation of patients. In the case of bleeding and IPDs,
the phenotypes can vary greatly from one individual to another
even with the same genotype. This makes it very difficult to
generate genotype–phenotype correlations and elucidate a dis-
ease-causing mechanism within these individuals. The first use
of NGS in IPDs identified NBEAL2 as the causative gene for grey
platelet syndrome (GPS) [37]. Many causative mutations within
the gene that encodes a BEACH domain protein cause differential
bleeding severities in individuals with GPS [38]. In the past few
years however, several research groups and their collaborators
have employed NGS to discover the causes of unexplained bleed-
ing; an example of a select few genes found using WES and/or
WGS can be seen in Table I.
The BRIDGE consortium was introduced as the NIHR
BioResource funded body for projects involving NGS related to
rare disease-causing variants. The BRIDGE-Bleeding and Platelet
Disorders (BDPs) study (B20) takes an alternative approach to the
discovery of novel and known variants by high throughput
sequencing (HTS) of a large patient cohort (>1000 donors) and
annotation with adapted Human Phenotype Ontology (HPO)
terms (https://bridgestudy.medschl.cam.ac.uk/bpd.shtml) [39].
Their aim is to characterize cases with similar HPO terms and
variants in the same gene to aid in gene discovery [39]. The
BRIDGE-BPD study used their novel approach to gene discovery
using HPO-encoded phenotype data for novel variants in ACTN1
along with other genes that have been implicated with bleeding
2 A. Maclachlan et al. Platelets, Early Online: 1–6
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including MYH9, ACTN1 being originally reported by Kunishima
et al. in 2013 [39,40]. ACTN1 mutations cause congenital macro-
thrombocytopenia as they affect the α-actinin protein involved in
the organization of the platelet cytoskeleton [40]. The platelet
macrocytosis indicates that the latest phases of megakaryopoiesis
are affected [41]. A gain-of-function mutation in SRC was also
found to cause bleeding and other bone pathologies following
WGS and HPO patient coding within the BRIDGE-BDP study
[42]. In order to ensure accurate annotation of the particular
phenotypes, the study added 80 terms and associated symptoms
to HPO in parallel with the development of the software hpoPlot
that summarizes the HPO codes of the cases [43]. It was hypothe-
sized that individuals with rare coding variants in the disease gene
would cluster on the basis of the HPO-encoded phenotypes they
were given upon recruitment to the study [39]. The data that was
generated suggested that despite minor anomalies, bleeding dis-
orders caused by common genetic backgrounds would tend to
cluster on the basis of their HPO terms [39]. This approach to
gene discovery was pioneered in bleeding and platelet disorders,
but is applicable to other rare diseases. The HPO data can be
linked to large online databases such as OMIM, which can be
used to prioritize disease gene candidates based on comparison to
other ontological phenotype terms from the scientific litera-
ture [39].
The Genotyping and Phenotyping of Platelets (GAPP) study
run from the University of Birmingham has recruited over 700
participants with bleeding disorders of unknown cause from over
25 collaborating Haemophilia Comprehensive Care Centres
across the UK and involves collaborations with the Universities
of Bristol, Nottingham and Sheffield (http://www.birmingham.ac.
uk/research/activity/cardiovascular-sciences/research/platelet-
group/platelet-gapp/index.aspx) [1]. The GAPP study team uses a
combination of platelet phenotyping and WES in a different
approach to variant discovery within platelet genomics with the
aim of identifying the likely causative gene(s) within each
recruited individual [1,44]. They emphasize the importance of
Table I. Novel genomic variants reported in genes recently discovered in patients with an inherited bleeding disorder following next-generation
sequencing. Gene and phenotypes associated with variants are shown. Heterozygous nucleotide changes (unless indicated) present in patients with
inherited bleeding and their predicted effects on the resulting RNA or protein are also shown. Genomic variations are numbered according to positions
in the publication of the reference indicated. dbSNP ID is given for each variant if known or is a novel variant not reported in the available databases.
Gene
Associated phenotypes Genomic variation Protein effect Variation type dbSNP ID Reference
NBEAL2 c.256 A>G p.Ile86Val Missense rs754407148 [37]
Thrombocytopenia,
large platelets,
lack of α-granules.
c.1163T>C p.Leu388Pro Missense rs387907113 [37]
c.1928 A>T p.Glu643Val Missense rs387907114 [37]
c.2044 >T p.Ile682Phe Missense rs773164015 [37]
c.6299 C>T p.Pro2100Leu Missense rs387907115 [37]
c.6802-2 A>AGGAGT Splice site [37]
c.6806 C>T p.Ser2269Leu Missense rs749896920 [12]
c.7658 G>A p.Gly2553Glu Missense rs144664865 [37]
ACTN1 c.64 G>A p.Asp22Asn Missense rs387907346 [41]
Thrombocytopenia,
large platelets
c.94 C>A p.Gln32Lys Missense rs747559032 [40]
. c.136 C>T p.Arg46Trp Missense rs387907348 [41]
c.137 G>A p.Arg46Gln Missense rs387907345 [40,41]
c.313 G>A p.Val105Ile Missense rs387907350 [40]
c.673 G>A p.Glu225Lys Missense [40,41]
c.751 G>C p.Gly251Arg Missense [41]
c.2210 C>A p.Thr737Asn Missense rs387907349 [41]
c.2212 C>T p.Arg738Trp Missense rs387907347 [40,41]
c.2255 G>A p.Arg752Gln Missense [40,41]
c.2289 G>A p.Gly764Ser Missense [41]
c.2305 G>A p.Glu769Lys Missense [41]
SRC c.1579 G>A p.Glu527Lys Missense [42]
Thrombocytopenia, sometimes large platelets,
lack of α-granules.
SLFN14 c.652 A>G p.Lys218Glu Missense [45]
Thrombocytopenia,
reduced δ-granules.
c.657 T>A p.Lys219Asn Missense [45]
c.659 T>A p.Val220Asp Missense [45]
c.667 C>T p.Arg223Trp Missense rs766076920 [7]
ETV6 c.641 C>T p.Pro214Leu Missense rs724159947 [49]
Thrombocytopenia,
hematologic malignancy.
c.1106 G>A p.Arg369Gln Missense rs724159946 [49]
c.1195 C>T p.Arg399Cys Missense rs724159945 [49]
FYB c.393 G>AHom p.Trp131StopHom Nonsense [51]
Thrombocytopenia,
small platelets.
PRKACG c.222 C>GHom p.Ile74MetHom Missense rs724159972 [52]
Thrombocytopenia,
giant platelets.
RBM8A c.-21 G>A Regulatory SNP rs139428292 [53]
Thrombocytopenia,
absence of radius bones.
c.67+32G>C Regulatory SNP rs201779890 [53]
DOI: 10.1080/09537104.2016.1195492 Inherited platelet disorders 3
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the genotype–phenotype correlation to improve the classification
and diagnosis of patients with novel or known platelet and bleed-
ing disorders [1]. However, since the phenotype can be the result
of multiple alleles with different pathogenic effects, interpreting
genetic variants remains difficult. Patients with novel SLFN14
variants as well as those with RUNX1 and FLI1 variants were
implicated in bleeding and discovered through the GAPP study
methodology, which shows effective proof of principle [45,46].
The SLFN14 variants were narrowed down from eight potential
disease-causing single nucleotide variants (SNVs) shared by the
three patients of the same family in the initial investigation. The
affected individuals present with thrombocytopenia and excessive
bleeding disproportionate to their platelet counts [45]. The plate-
lets also have a reduced number of δ-granules and therefore ADP
secretion is also reduced [45]. The GAPP study continues to
recruit patients from their collaborating hemophilia centers in
the UK and beyond.
The ThromboGenomics platform has also been implementing
NGS with regard to bleeding, thrombotic and platelet disorders
(http://www.thrombogenomics.org.uk). They have developed a
targeted gene capture platform that encompasses approximately
70 candidate genes with the aim of providing a multi-gene high-
throughput sequencing platform to obtain diagnoses for patients
with suspected bleeding or platelet disorders [47]. Again the use
of the HPO term-based coding of patient phenotypes is being
utilized in order to elucidate genotype–phenotype correlations
[47]. The ThromboGenomics platform has used WGS data and
is critically dependent on the recruitment of patients with strong,
clinically well-characterized phenotypes. WES has been carried
out on the genes ITGA2B and ITGB3 with input from
ThromboGenomics in order to identify novel variants within
these genes and predict whether the said variants are likely to
cause Glanzmann Thrombasthenia [48]. ThromboGenomics has
multiple national and international collaborators that are involved
at various levels to continue the development of the platform.
Other genes implicated in IPDs have been discovered outside
of the main research groups by NGS technologies. Variants within
the gene ETV6 have recently been shown to cause thrombocyto-
penia with susceptibility to hematologic malignancy [49]. WES of
the affected family members in the study group was carried out to
discover five potential protein altering variants [49]. However,
Sanger sequencing confirmed the heterozygous germline ETV6
variant as the definite cause of their bleeding phenotype [49]. The
known pathogenic variant of FYB also causes thrombocytopenia
along with a reduced percentage of mature platelets in the bone
marrow [50,51]. This was discovered following WES, homozyg-
osity mapping and extensive Sanger sequencing and genotyping
where the segregation of the variant was confirmed [50]. A
mutation in the PRKACG gene has been identified to cause a
new form of macrothrombocytopenia as it leads to a defect in
proplatelet formation [52]. Again this discovery was enabled by
WES of the proband, another affected individual and other
healthy family members [52]. As in most cases, other variants
were found through bioinformatic analysis, but as PRKACG is
highly conserved and implicated in platelet processes this
remained their best candidate [52]. Mutations in the regulatory
regions of the gene RBM8A are now known to cause thrombocy-
topenia with absent radii (TAR) syndrome, again discovered by
WES [37,53]. These advances illustrate the importance and recent
increase in the popularity of using NGS to discover genetic
variants in IPDs.
Challenges and opportunities
One of the main challenges arises with the development of bioin-
formatic analysis tools that are already lagging behind the
advances in the substantial amount of data generated by NGS.
This often leads to the analysis of bioinformatic data post NGS
being the rate-limiting step in the process of gene identification.
Therefore, the second challenge faced within platelet genomics is
the identification of the causal gene and variant among multiple
possible variants and link it to disease and function [34]. This is
often equivocal and several candidates remain. Presently,
sequence variant analysis is imperfect and a tremendous amount
of work is needed to introduce a large-scale statistical automated
framework for the calling of variants [54,55]. There have been
standards and guidelines published for the interpretation of
sequence variants as recommended from the American College
of Medical Genetics and Genomics (ACMG) and the Association
for Molecular Pathology [54]. The report recommends the use of
specific consensus terminology – ‘pathogenic’, ‘likely patho-
genic’, ‘uncertain significance’, ‘likely benign’ and ‘benign’ to
describe variants identified in possible disease-causing genes
based on evidence for a set of criteria and the strength of the
criteria [54]. Another potential challenge arises with the inevita-
ble discovery of genetic variants not related to the disease state in
question, the so-called incidental or secondary findings [56]. This
is a complex issue with many confounding factors involving
ethics. The issue faced by clinicians is, should they disclose
secondary findings with potential clinical relevance to their
patients and if so, when and how? The interpretation of the
information delivered would require education and in relation to
some inherited bleeding disorders possible genetic counseling.
The ACMG has published a policy statement concerning NGS
with emphasis on incidental findings in clinical pretesting, genetic
testing and the reporting of results [57]. The recommendations of
the ACMG Working Group on Incidental Findings in Clinical
Exome and Genome Sequencing have also been published and
outline a list conditions, genes and variants they recommend for
return of incidental findings in clinical sequencing [58]. This is
deemed by many to go beyond targeted sequencing and true
incidental findings to suggest automatic screening for genetic
conditions in all patients undergoing WES/WGS [59]. It is a
controversial area of interest that requires further social and
professional debate, which should both proceed with ethical cau-
tion and concern [59].
It is all very well being able to elucidate mutations from rare
disease-causing variants; however, the view that there is little
purpose in finding the genetic causes of diseases is held by
some. This is because slow progress has been made improving
the understanding of the consequences of the genetic variants we
already know about [33]. What has been discovered to cause
bleeding through NGS though suggests that this argument does
not hold. We now have knowledge of platelet genes that are
known or predicted to have a role in the regulation of platelets
along with platelet physiological processes and we are therefore
able to diagnose patients with specific IPDs as a result [5]. It is
important to emphasize the need for cell biology to explore novel
unclassified variants in order to investigate expression analysis
and protein function to ensure a variant is well characterized and
proven to be functionally disrupting [1]. As more data is accu-
mulated about the genetics of bleeding and platelet disorders, the
list of candidate variants will decrease. Therefore, the likelihood
of finding a disease-causing mutation improves even within plate-
let defects where this will always remain a challenge due to their
multifactorial nature [33].
Conclusion
The advances that have been described impact the medical manage-
ment of individuals suffering from IPDs and provide insights into
the mechanisms of diseases [34]. Future directions following WES
4 A. Maclachlan et al. Platelets, Early Online: 1–6
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are to employ WGS to search for mutations in observed bleeding
phenotype–genotype mismatches. WGS does have comprehensive
genomic coverage but is extremely limited in its use by its high
price, although this is now reducing, and heavy analytical burden.
Once these issues have been addressed and the bioinformatics tools
have been improved and made more user-friendly; along with
databases improving with more and more variants being deposited
into the said databases, it may become the sequencing technology
of choice for many. However, a sustained collaboration among
research scientists, clinicians and commercial vendors, for the
machines and materials needed, is required for this next phase of
NGS [60]. For the moment though, WES is highly successful and
this robust genetic technique will remain at the forefront of platelet
genomic research.
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